# Geron Plans to Discontinue Late-Stage Rytelo Trial After Efficacy Concerns

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/42891
Published: 2026-10-28T19:54:09.000Z
Updated: 2026-10-28T19:54:09.000Z
Section: Business

> Geron shares fell more than 20% Wednesday as the company moved to end the study.

The planned discontinuation applies to a late-stage study of imetelstat, Geron’s lead asset, which the company markets as Rytelo. The move followed concerns about the drug’s efficacy. Geron shares fell more than 20% Wednesday, Oct. 28.